Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Doxazosin Japanese marketed IR · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | Doxazosin 4 mg Japanese marketed IR tablet as a single oral dose under fasted conditions |
| B | EXPERIMENTAL | Doxazosin 4 mg ODT with water as a single oral dose under fasted conditions |
| C | EXPERIMENTAL | Doxazosin 4 mg ODT without water as a single oral dose under fasted conditions |
| Name | Type | Description |
|---|---|---|
| Doxazosin 4 mg Japanese marketed IR tablet | DRUG | Immediate release tablet, 4 mg, single dose |
| Doxazosin 4 mg ODT with water | DRUG | Orally-disintegrating Tablet , 4 mg, single dose with water |
| Doxazosin 4 mg ODT without water | DRUG | Orally-disintegrating Tablet , 4 mg, single dose without water |
Inclusion Criteria: * Japanese healthy male subjects Exclusion Criteria: * Baseline orthostatic hypotension defined as a ≥20 mm Hg reduction in SBP, a ≥10 mm Hg reduction in DBP and/or the development of significant postural symptoms (dizziness, lightheadedness, vertigo) when going from the supin...
Doxazosin Japanese marketed IR is a small molecule being studied for the treatment of hypertension. It is an immediate release formulation of doxazosin, developed by Pfizer, Inc. The drug is currently in Phase 1 clinical development for this cardiovascular condition.
Doxazosin Japanese marketed IR is developed by Pfizer, Inc., a company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is being investigated as a treatment for hypertension.
Doxazosin Japanese marketed IR is in Phase 1 clinical development. It is an investigational drug being studied for hypertension. A Phase 1 bioequivalence study has been completed, and the drug has not yet been approved by regulatory authorities.
Doxazosin Japanese marketed IR has one completed clinical trial, NCT01389609. This Phase 1 study evaluated the bioequivalence of a 4 mg orally-disintegrating tablet with or without water compared to the 4 mg Japanese marketed immediate release tablet under fasted conditions. The trial enrolled 24 healthy male volunteers in Japan.
Doxazosin Japanese marketed IR is a specific immediate release formulation of doxazosin, a drug used for hypertension. It is being studied as a reference product in a bioequivalence trial. The drug is developed by Pfizer, Inc. and is currently in Phase 1 clinical development.